Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer.

CONCLUSIONS: The combination of BCL2 and Wee1 inhibition presents a novel therapeutic strategy for the treatment of SCNPC.
PMID: 31806643 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 4, 2019 Category: Cancer & Oncology Authors: Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown L, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS Tags: Clin Cancer Res Source Type: research